HDAC9 and amyotrophic lateral sclerosis: We previously reported that the combined administration of low doses of the class-I HDAC inhibitor entinostat (MS-275) and RESV promote the normalization of the RelA acetylation state and revert the pathological histone H3 deacetylation in brain ischemia as well as ALS animal models [31,37].